On August 22, 2022, the National Medical Innovation Development and R & D Cooperation Forum and the Pharmaceutical New Technology Laowen Trading Expo 2022 Nanjing Station was opened at the Shangri -La Hotel in Nanjing. Jiangsu Farmasino Co., Ltd. was invited to participate in the exhibition and fully demonstrated the six cores. Business, consolidate existing cooperative relationships, discover potential customers, and lay the foundation for developing the market. This meeting was hosted by the Community of Pharmaceutical Destiny and BIO-WELCOME. It was hosted by future Huihui Pharmaceutical Technology (Beijing) Co., Ltd., which brought together many Chinese entrepreneurs and executives. "Industry resources and intelligence concentrated high areas." The meeting builds a platform for the industry to promote information circulation and help the rapid development of the industry. At the same time, it provides enterprises with more industry exchanges and business expansion opportunities to help enterprises quickly find: CROs are highly difficult technologies such as new drugs, 505B2, etc. Products and other resources.

FarmaSino 's 2022 year-end summary conference. On January 8, FarmaSino Co., Ltd. held the 2022 annual work summary and advanced commendation conference in the conference room of the headquarters building. At the beginning of the meeting, the leaders of various departments reported the business results in 2022, comprehensively analyzed the gains and losses in the work, and planned and looked forward to the work in 2023. Next, the company recognized the advanced individuals and teams that emerged this year. The last session of the conference was delivered by Yan Libo, Chairman of FarmaSino, who introduced to all employees the company's brilliant performance in 2022, and the company's sales exceeded 200 million US dollars for the first time since its establishment, an increase of more than 30% year-on-year, achieving a milestone leap in business performance.

Farmasino 's strategic investment shareholder Novezan was listed on the Science and Technology Innovation Board! The total market capitalization exceeds 37 billion! On the morning of November 15, 2021, Nanjing Novezan Biotechnology Co., Ltd., a strategic investment shareholder of Farmasino, was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange. Stock abbreviation: Novezan Stock code: 688105. Founded in 2012, Nanjing Novezan Biotechnology Co., Ltd. is a biotechnology enterprise focusing on enzymes, antigens, antibodies and other functional proteins and polymer organic materials for technology research and development and product development, relying on the key common technology platform independently established, has entered the field of biological reagents, in vitro diagnostic business, and is conducting the research and development of antibody drugs, is one of the few domestic R & D innovative enterprises with independent and controllable upstream technology development capabilities and terminal product production capacity.